Porokeratoses: an update on pathogenesis and treatment

  • 0School of Medicine, European University of Cyprus, Nicosia, Cyprus.

|

|

Summary

This summary is machine-generated.

Porokeratoses (PK) are rare skin disorders caused by mevalonate pathway defects. New topical treatments combining statins and cholesterol show improved efficacy for managing this condition.

Area Of Science

  • Dermatology
  • Genetics
  • Biochemistry

Background

  • Porokeratoses (PK) are uncommon dermatoses with abnormal epidermal differentiation.
  • They stem from a disorder in the mevalonate metabolic pathway.
  • PK exhibits diverse clinical subtypes and a characteristic histopathologic finding, the cornoid lamella.

Purpose Of The Study

  • To elucidate the pathogenesis of Porokeratoses.
  • To explore the genetic basis and inheritance patterns of PK.
  • To evaluate current and novel therapeutic strategies for PK.

Main Methods

  • Genetic analysis to identify pathogenic variants in the mevalonate pathway.
  • Histopathological examination to confirm the cornoid lamella.
  • Clinical evaluation of treatment efficacy for various PK subtypes.

Main Results

  • Pathogenesis linked to germline variants in the mevalonate pathway, requiring a second hit.
  • PK is dominantly inherited but recessively expressed.
  • New topical treatments (statins and cholesterol) demonstrate improved efficacy over older methods.

Conclusions

  • The mevalonate metabolic pathway is central to PK pathogenesis.
  • Understanding the genetic basis informs inheritance patterns and management.
  • Novel topical treatments offer more consistent efficacy for Porokeratoses.